The permanent neurological deficits of multiple sclerosis patients largely depend on the extent of degeneration of long nerve fibers. The latter is initiated by ruptures in the cell membrane and ...

Multiple sclerosis attacks and damages the central nervous system, producing symptoms such as muscle weakness, trouble with coordination and balance, vision problems, and thinking and memory ...

We initiate coverage on Axon with a Sell rating and $608 PT, citing valuation risk despite robust growth and execution. Axon’s premium multiple is vulnerable to structural macro headwinds—high ...

Multiple Sclerosis diagnoses have been rising globally since 2013, and in 2019, an estimated 1 million people had MS. Doctors are trying to figure out why.

Patient-reported outcomes in multiple sclerosis matter but remain underused due to multiple barriers.

Other than ALS, the device could also help patients with cerebral palsy, multiple sclerosis, epilepsy, and other such conditions.

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...

While AXON stock looks fully valued, it is helpful to see other valuable comparisons for companies across industries at Peer Comparisons. Separately, look at what’s happening with Delta stock.

Young Black and Hispanic women with multiple sclerosis fare worse than young white women with the disease. Minority women were more likely to have more advanced disease and faced greater challenges in ...

New data suggest the frequency of damage and repair processes correlates with disease severity and disability in multiple sclerosis (MS).

Multiple sclerosis was once seen as a “dead-end disease.” But lots of little interventions have added up to remarkable progress. Should that change how we take on other conditions?